AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible… Read More
VANCOUVER, BC –– InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its… Read More
The poster at ADA 2022 will highlight the development of Aspect’s bioengineered pancreatic tissue therapeutic VANCOUVER, B.C. – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics… Read More
STEMCELL Technologies Inc. and PBS Biotech Inc. have announced their supply partnership to make the PBS-MINI Bioreactor available through STEMCELL Technologies for researchers looking to scale up their human pluripotent stem cell… Read More
VANCOUVER, BC – Genomic research is leading to incredible advances in modern-day healthcare but combining health and genomic data can greatly accelerate new discoveries. To enable the advancement of medical research… Read More
